Biomednewsbreaks - Adageis's Platform Empowering Organizations To Adjust To New Risk-Scoring Dynamics

(MENAFN- Investor Brand Network) Adageis , a forward-thinking healthcare technology company reshaping patient care through flexible AI-centric software solutions, is in support of the Centers for Medicare and Medicaid Services' (“CMS”) switching from the V24 to the V28 upgrade of the Hierarchical Condition Categories (“HCC”) model.“The transition from CMS-HCC V24 to V28 reflects a critical update to the risk adjustment model used in Medicare Advantage... The more precise structure enhances diagnostic specificity, allowing for better patient categorization. This change supports value-based care by tying payments more closely to actual patient needs,” reads a recent article.

“The CMS-HCC transition aligns closely with Adageis's mission of revolutionizing patient care through innovative value-based care solutions. The company's ProActive Care Platform leverages AI-driven predictive analytics to optimize care and reimbursement, making it uniquely suited to help healthcare providers navigate these changes... By integrating seamlessly with existing electronic medical records ('EMRs') and reducing the barriers to adoption, Adageis empowers organizations to meet the challenges of the V28 model. The platform's ability to identify high-risk patients and streamline care planning is crucial as providers adjust to new risk-scoring dynamics.”

To view the full article, visit

About Adageis
Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector. For more information, visit the company's website at
.

NOTE TO INVESTORS:
The latest news and updates relating to Adageis are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN13012025000224011066ID1109086673